TOP > クイック検索 > 外国特許検索 > NON-PEPTIDIC GAPDH AGGREGATION INHIBITOR

NON-PEPTIDIC GAPDH AGGREGATION INHIBITOR NEW

外国特許コード F170009135
整理番号 S2015-1593-C0
掲載日 2017年7月20日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP066999
国際公開番号 WO 2016199796
国際出願日 平成28年6月8日(2016.6.8)
国際公開日 平成28年12月15日(2016.12.15)
優先権データ
  • 特願2015-116140 (2015.6.8) JP
発明の名称 (英語) NON-PEPTIDIC GAPDH AGGREGATION INHIBITOR NEW
発明の概要(英語) [Problem] To provide a novel non-peptidic compound that can be used as a GAPDH aggregation inhibitor. [Solution] Provided is a GAPDH aggregation inhibitor which contains, as an active ingredient, a compound represented by chemical formula 1 (wherein R1, R2 and R3 independently represent a hydrogen atom, a halogen atom, or an aliphatic hydrocarbon group having 1 to 10 carbon atoms inclusive), or a polysulfurized derivative or a pharmacologically acceptable salt thereof. The compound has a GAPDH aggregation-inhibiting activity, and therefore can inhibit the aggregation of various proteins associated with cerebral neurodegenerative diseases in the brain to contribute to the amelioration of various cerebral nerve diseases associated with the aggregation of the proteins, such as Alzheimer's disease, Parkinson's disease and cerebral infarction, or to the prevention of these diseases from becoming severe.
特許請求の範囲(英語) [claim1]
1. Chemical formula 1 (however, R in formula [1], R [2], R [3] the hydrogen atom, the halogen atom, or the number of carbon atoms is the aliphatic hydrocarbon radical of 10 or less of 1 or more in the respective independence.)So the poly- sulfur conversion derivative of the chemical compound which is shown or the chemical compound which is shown with chemical formula 1, and the salt where those are allowed pharmacology.
[claim2]
2. Chemical formula 1 (however, R in formula [1], R [2], R [3] the hydrogen atom, the halogen atom, or the number of carbon atoms is the aliphatic hydrocarbon radical of 10 or less of 1 or more in the respective independence.)So the poly- sulfur conversion derivative of the chemical compound which is shown and the chemical compound which is shown with chemical formula 1, the GAPDH cohesion inhibiter which designates the chemical compound of 1 or more where it is chosen from the group which consists of the salt where those are allowed pharmacology as the active ingredient.
[claim3]
3. The medicine composition which contains the chemical compound of statement in claim 1.
[claim4]
4. In claim 3 in order prevents the cranial nerve denaturation disease or the condition, it remedies or to improve the medicine composition of statement.
[claim5]
5. As for the aforementioned cranial nerve denaturation disease, the Alzheimer's disease, the parkinson's disease and the [hanchinton] illness, in the claim 4 which is either of the brain blockages the medicine composition of statement.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • OSAKA PREFECTURE UNIVERSITY
  • 発明者(英語)
  • NAKAJIMA HIDEMITSU
国際特許分類(IPC)
指定国 (WO2016199796)
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG

PAGE TOP

close
close
close
close
close
close